Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits

Abstract

A method for preventing clotting in an extracorporeal blood circuit by administering a synthetic oligosaccharide that is a selective inhibitor of factor Xa, acting via antithrombin III.

1 . A use of a synthetic oligosaccharide which is a selective inhibitor of factor Xa, acting via antithrombin III, for the manufacture of a medicament for preventing blood clotting in patients with an extracorporeal blood circuit.  
     
     
         2 . The use according to  claim 1 , wherein the oligosaccharide is the pentasaccharide methyl O-(2-deoxy-2-sulphoamino-6-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(β-D-glucopyranosyl uronic acid)-(1→4)-O-(2-deoxy-2-sulphoamino-3,6-di-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2-O-sulpho-α-L-idopyranosyl uronic acid)-(1→4)-2-deoxy-2-sulphoamino-6-O-sulpho-α-D-glucopyranoside or a pharmaceutically acceptable salt thereof.  
     
     
         3 . The use of  claim 2 , wherein the pentasaccharide is in the form of its decasodium salt.  
     
     
         4 . The use according to any one of claims  1 - 3 , wherein the extracorporeal blood circuit is of haemodialysis patients.  
     
     
         5 . The use according to any one of claims  1 - 4 , wherein the medicament is suitable for intravenous administration.  
     
     
         6 . The use according to any one of claims  1 - 4 , wherein the medicament is adapted for use as an anticoagulant coating.  
     
     
         7 . The use according to any one of claims  1 - 6 , wherein the medicament is in a unit dosage form.  
     
     
         8 . A method of preventing blood clotting in a mammal undergoing a treatment in which an extracorporeal blood circuit is used, comprising the administration to said mammal of a therapeutically effective amount of the oligosaccharide as defined in  claim 1  or  2  or a pharmaceutically acceptable salt thereof.  
     
     
         9 . A method of preventing blood clotting in an extracorporeal blood circuit, comprising furnishing components of the circuit with a therapeutically effective amount of the oligosaccharide as defined in  claim 1  or  2 , or a pharmaceutically acceptable salt thereof.  
     
     
         10 . A pharmaceutical composition adapted for preventing blood clotting in an extracorporeal blood circuit comprising the oligosaccharide as defined in  claim 1  or  2 , or a pharmaceutically acceptable salt thereof, together with pharmaceutically acceptable auxiliaries.